Tarsus Pharmaceuticals, Inc. (TARS)
Nasdaq: TARS · Biological Products, (No Diagnostic Substances) · Irvine, CA · filing with the SEC since 2020
Who owns Tarsus Pharmaceuticals, Inc.
As filed with the SECHolders of 5% or more
4
Deep Track Capital, LP holds 8.46% of Common Stock, $0.0001 par value per share, as its SCHEDULE 13G/A filed May 15, 2026 says.
Directors and officers
15
report now, of 21 people on the record since 2020. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
Deep Track Capital, LP
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, $0.0001 par value per share · 7.11% in Nov 14, 2025
RTW Investments, LP
SCHEDULE 13G/A · filed Aug 14, 2025 · Common Stock, par value $0.0001 per share
Blackrock, Inc.
SCHEDULE 13G/A · filed Apr 24, 2025 · Common Stock
JANUS HENDERSON GROUP Ltd.
SCHEDULE 13G/A · filed Aug 13, 2026 · Common Stock · 5.3% in May 15, 2026
Cowen Financial Products LLC
SCHEDULE 13G/A · filed Feb 13, 2025 · Common Stock, $0.0001 par value per share · reported falling below 5%
Morgan Stanley
SCHEDULE 13G/A · filed May 7, 2025 · Common Stock · reported falling below 5%
Prudential Financial, Inc.
SCHEDULE 13G/A · filed May 8, 2026 · Common · reported falling below 5%
Jennison Associates LLC
SCHEDULE 13G/A · filed May 6, 2026 · Common Stock · reported falling below 5%
Tang Capital Management, LLC
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 5.9% in May 15, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%
What TARS reports owning in othersstakes of 5% or more, and other ties
Tarsus Pharmaceuticals, Inc. reports no stake in another company in the record.
Insider tradesForm 4
59sales
0purchases
36sales on a scheduled plan
9people selling
$20.0Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 5, 2025 to Nov 5, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 5, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window9 of 31 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Azamian Bobak R. | President/CEO and Board Chair | 10 | $5.2M | 7 | 0 | $0 |
| Link William J Phd | director | 13 | $4.5M | 13 | 0 | $0 |
| Whitfield Dianne C. | Chief Human Resources Officer | 8 | $2.7M | 5 | 0 | $0 |
| Lin Elizabeth Yeu | Chief Medical Officer | 11 | $2.4M | 7 | 0 | $0 |
| Neervannan Seshadri | Chief Operating Officer | 6 | $2.0M | 3 | 0 | $0 |
| Farrow Jeffrey S | Chief Financial Officer and Chief Strategy Officer | 4 | $1.3M | 0 | 0 | $0 |
| Mottiwala Aziz | Chief Commercial Officer | 3 | $900,000 | 0 | 0 | $0 |
| Wahl Bryan | General Counsel | 3 | $900,000 | 0 | 0 | $0 |
| Goodrich Katherine | director | 1 | $200,000 | 1 | 0 | $0 |